Bodytechmed Enters French Market with Therapeutic Drug Monitoring Product... Signs OBL Supply Agreement

[Asia Economy Reporter Lee Gwan-joo] Boditech Med announced on the 2nd that it has signed an Own Brand Label (OBL) supply contract for Therapeutic Drug Monitoring (TDM) products with the French diagnostic company Theradiag.

Through this contract, Boditech Med will supply its TDM products, including infliximab, anti-infliximab, adalimumab, and anti-adalimumab, under the OBL method, and Theradiag plans to sell these products in the European market under the ‘ez-Track1 and ez-Tracker’ brands.

Theradiag is a company with 30 years of experience in manufacturing and distributing in vitro diagnostic devices and is one of the leading companies in the global TDM market for antibody therapeutics. It currently operates in more than 70 countries worldwide and recorded sales of 11.1 million euros (approximately 15 billion KRW) last year.

TDM measures the concentration of administered drugs in the blood, testing whether the blood drug concentration is within the therapeutic range. As the global antibody therapeutic market is rapidly growing, the demand for TDM products is also expected to continuously increase.

Bertrand de Castelnau, CEO of Theradiag, said, “TDM products, which enhance testing convenience with fast and accurate diagnostics in the global healthcare market and provide patient-tailored treatments, are gaining attention. Through this contract with Boditech Med, we can introduce products with innovative quality to the European market.”

Choi Eui-yeol, CEO of Boditech Med, said, “We will continue relentless research and development and marketing activities to increase the market share of the TDM product line, which we consider our next growth engine, in the global market.”

This content was produced with the assistance of AI translation services.